23-Valent Pneumococcal Polysaccharide Vaccine Market was valued at USD 0.94 Billion in 2022 and is projected to reach USD 1.27 Billion by 2030, growing at a CAGR of 4.1% from 2024 to 2030.
The 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) is designed to protect individuals against pneumococcal infections caused by 23 different strains of the bacteria Streptococcus pneumoniae. This vaccine is primarily administered in different age groups based on their susceptibility to pneumococcal diseases. The vaccine is especially crucial in preventing conditions like pneumonia, meningitis, and bacteremia, which can cause severe complications, especially in vulnerable populations. The market for this vaccine is expanding as awareness about pneumococcal infections grows, particularly in the context of the increasing aging population and the heightened risk factors associated with chronic diseases such as diabetes, heart disease, and respiratory conditions. The demand for PPSV23 is influenced by the prevalence of pneumococcal disease in different regions, healthcare policies, and vaccination programs aimed at protecting high-risk populations.
Download Full PDF Sample Copy of Global 23-Valent Pneumococcal Polysaccharide Vaccine Report @ https://www.verifiedmarketreports.com/download-sample/?rid=41104&utm_source=Google_site&utm_medium=231
The 23-Valent Pneumococcal Polysaccharide Vaccine is used in children aged 2 to 10 years primarily for those who are at higher risk of pneumococcal diseases due to underlying health conditions. While pneumococcal diseases are less common in healthy children, those with conditions such as sickle cell disease, HIV, or chronic heart or lung disease are more susceptible. In this age group, vaccination is essential to prevent the onset of serious infections such as pneumonia, meningitis, and ear infections. The vaccination also provides an additional layer of protection during childhood immunization schedules to ensure long-term immunity against the most common pneumococcal strains. The 23-valent vaccine plays a key role in reducing the burden of these infections and helps avoid complications that can impact the child’s health, growth, and development.For this subsegment, healthcare providers generally recommend vaccination for children in high-risk categories, and it is often included in public health immunization programs in many countries. The widespread use of this vaccine in childhood programs has shown to significantly reduce the rates of hospitalization due to pneumococcal diseases. Moreover, it helps to minimize the transmission of pneumococcus, contributing to community-level immunity. This not only protects the vaccinated child but also shields those who are immunocompromised or unable to receive the vaccine due to medical reasons. The growth of the 23-Valent Pneumococcal Polysaccharide Vaccine market within this group is driven by increasing awareness and advancements in pediatric healthcare policies.
The 23-Valent Pneumococcal Polysaccharide Vaccine for individuals aged 10 to 64 is primarily targeted at those who are at moderate risk for pneumococcal disease. This includes people with chronic conditions such as asthma, diabetes, or lung diseases like chronic obstructive pulmonary disease (COPD). Individuals in this age group without these risk factors are generally less likely to receive the vaccine unless mandated by public health guidelines or specific risk circumstances. In recent years, there has been a growing recognition of the need to vaccinate this population to prevent pneumococcal infections, especially in light of emerging diseases and the potential for pneumococcal bacteria to cause outbreaks. The vaccine also serves as a preventive measure for those in the workforce or school-age population who may be exposed to high-risk environments, such as crowded settings or international travel to areas with higher rates of pneumococcal disease.In addition to chronic illness, factors such as smoking, alcohol consumption, and immunosuppressive treatments contribute to an increased risk of pneumococcal infections within this age group. The market for this segment is expected to expand as awareness increases about the importance of preventive vaccination for individuals with these risk factors. As such, vaccination programs in countries with aging populations and rising healthcare costs may drive increased adoption of the vaccine for adults. Health campaigns and greater access to the vaccine through pharmacies, healthcare facilities, and public health initiatives are expected to further boost market growth in this subsegment. The strategic use of vaccines to address preventable diseases is considered a cornerstone of cost-effective public health approaches for this group.
The 23-Valent Pneumococcal Polysaccharide Vaccine is most commonly administered to individuals aged 65 and above, as this age group is at the highest risk of developing severe complications from pneumococcal infections. The elderly are more vulnerable due to a combination of age-related decline in immune function, the presence of chronic illnesses, and the higher likelihood of requiring hospitalization for respiratory illnesses. This population group is often prioritized in vaccination programs, as pneumococcal diseases like pneumonia and meningitis are leading causes of morbidity and mortality in older adults. The PPSV23 vaccine helps to significantly reduce the incidence of these diseases and their associated complications, such as prolonged hospital stays, higher treatment costs, and even death.With the global aging population steadily increasing, the demand for the 23-Valent Pneumococcal Polysaccharide Vaccine is expected to rise sharply. The World Health Organization (WHO) and national health authorities recommend routine vaccination for older adults, especially those with additional risk factors such as cardiovascular disease, diabetes, and respiratory conditions. This subsegment accounts for the largest share of the 23-Valent Pneumococcal Polysaccharide Vaccine market, and its expansion is supported by increasing recognition of the vaccine's cost-saving potential by reducing healthcare costs associated with severe pneumococcal infections. Public health initiatives and government-backed vaccination programs aimed at the elderly will continue to drive the growth of this market.
The 23-Valent Pneumococcal Polysaccharide Vaccine market is poised for growth, driven by several key trends and emerging opportunities. One of the most significant trends is the growing recognition of the vaccine’s importance in preventing severe infections among high-risk populations, especially the elderly and children with underlying health conditions. Public health awareness campaigns and government mandates in many countries are playing a crucial role in expanding vaccine coverage and encouraging vaccination among high-risk individuals. Furthermore, the continued development of healthcare infrastructure in emerging markets is opening new opportunities for vaccine manufacturers to introduce and distribute PPSV23.Another trend is the increased focus on preventive healthcare, as governments and healthcare systems seek to reduce the financial burden of treating infectious diseases. Pneumococcal vaccination programs are considered a cost-effective strategy for preventing long-term health complications, hospitalizations, and deaths. The opportunity to expand vaccination coverage in low-income regions and rural areas also presents a significant market opportunity for vaccine developers and distributors. In addition, as more people become aware of the risks associated with pneumococcal diseases and their impact on public health, there is a growing opportunity for the 23-Valent Pneumococcal Polysaccharide Vaccine market to expand beyond its traditional age group targets and reach a broader demographic base.
1. What is the 23-Valent Pneumococcal Polysaccharide Vaccine used for?
It is used to protect against 23 strains of pneumococcal bacteria, which can cause pneumonia, meningitis, and bacteremia.
2. Who should get the 23-Valent Pneumococcal Polysaccharide Vaccine?
It is recommended for children with certain health conditions, adults aged 65+, and people with chronic illnesses or weakened immune systems.
3. Is the 23-Valent Pneumococcal Polysaccharide Vaccine safe?
Yes, it is considered safe and effective for most people, though like all vaccines, it may cause mild side effects such as soreness at the injection site.
4. Can the 23-Valent Pneumococcal Polysaccharide Vaccine prevent all pneumococcal diseases?
While it protects against 23 strains, it does not cover all pneumococcal bacteria, so additional vaccines may be recommended in some cases.
5. How long does immunity last after receiving the 23-Valent Pneumococcal Polysaccharide Vaccine?
Immunity can last for several years, but some people may need booster doses, especially those with certain medical conditions.
6. What are the common side effects of the 23-Valent Pneumococcal Polysaccharide Vaccine?
Common side effects include pain at the injection site, redness, swelling, fever, and fatigue, but these are typically short-lived.
7. Is the 23-Valent Pneumococcal Polysaccharide Vaccine necessary for healthy adults?
It is generally not recommended for healthy adults without risk factors, but it is important for those with chronic health conditions.
8. How effective is the 23-Valent Pneumococcal Polysaccharide Vaccine?
The vaccine is highly effective at preventing severe pneumococcal infections in high-risk individuals, though its effectiveness may vary by age and health status.
9. Can pregnant women receive the 23-Valent Pneumococcal Polysaccharide Vaccine?
Pregnant women are typically advised not to receive this vaccine unless they have a high risk for pneumococcal disease, as safety data is limited.
10. Are there any alternatives to the 23-Valent Pneumococcal Polysaccharide Vaccine?
Yes, there is the 13-Valent Pneumococcal Conjugate Vaccine (PCV13), which offers protection against a different set of pneumococcal strains, often used in combination with PPSV23.
```
Download Full PDF Sample Copy of Global 23-Valent Pneumococcal Polysaccharide Vaccine Report @ https://www.verifiedmarketreports.com/download-sample/?rid=41104&utm_source=Google_site&utm_medium=231
MSD
Sanofipasteur
CDIBP
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase Of This Report @ https://www.verifiedmarketreports.com/ask-for-discount/?rid=41104&utm_source=Google_site&utm_medium=231
Growing demand for below applications around the world has had a direct impact on the growth of the Global 23-Valent Pneumococcal Polysaccharide Vaccine Market
For Children (2-10)
For Person (10-64)
For The Old (>65)
Based on Types the Market is categorized into Below types that held the largest 23-Valent Pneumococcal Polysaccharide Vaccine market share In 2023.
Single Dose Vial
Pre-filled Syringe
Global (United States, Global and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ https://www.verifiedmarketreports.com/product/global-23-valent-pneumococcal-polysaccharide-vaccine-market-2019-by-manufacturers-regions-type-and-application-forecast-to-2024/
1. Introduction of the Global 23-Valent Pneumococcal Polysaccharide Vaccine Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, By Type
6. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, By Application
7. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market, By Geography
Global
Europe
Asia Pacific
Rest of the World
8. Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/